Dramatic post-cardiotomy outcome, due to severe anaphylactic reaction to protamine by Panos, A. et al.
Case report
Dramatic post-cardiotomy outcome, due to severe
anaphylactic reaction to protamine
A. Panos*, X. Orrit, C. Chevalley, A. Kalangos
Clinic for cardio-vascular surgery, Department of Surgery, University Hospital of Geneva, 24, rue Micheli-du-Crest, 1211 Geneva 14, Switzerland
Received 17 December 2002; received in revised form 28 March 2003; accepted 1 April 2003
Abstract
Immunologic reactions to protamine sulfate during cardiac surgery are very rare. The frequency and outcome of such adverse reactions is
unclear. We report a case of lethal anaphylactic reaction to protamine that occurred in a non-diabetic patient following the uneventful
replacement of the ascending aorta. We also briefly review the mechanisms of this adverse reaction and emit some considerations on the
management of this situation.
q 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Protamine is a polycationic peptide that is mainly used
to reverse the anticoagulant effects of heparin. Although
protamine is a relatively safe drug, it is occasionally
associated with a severe systemic reaction and significant
morbidity and mortality [1].
A 64-year-old male, with a history of smoking and
arterial hypertension, but no diabetes mellitus, was admitted
for a symptomatic aneurysm of the ascending aorta diag-
nosed by computed tomography (CT)-scanner. Echocardio-
graphy showed severe aortic valve insufficiency, but no
signs of aortic wall rupture. Coronary angiography revealed
normal coronary arteries. The patient was transferred to the
operating room. Femoro-femoral cardiopulmonary bypass
(CPB) was initiated, the patient was cooled to 308C and
antegrade blood cardioplegia was administered in the
coronary ostia. The aortic aneurysm was resected and
replaced by a 26 mm Dacron tube (Sulzer Medica)
according to Tirone David’s technique. Total aortic cross-
clamping time was 61 min. The patient was successfully
weaned from CPB with no inotropic support. Heparin was
reversed by a slow intravenous injection of 40,000 IU
protamine sulfate. Ten minutes after the complete admin-
istration of protamine, rapid right ventricular dilatation was
observed. Mean systemic and pulmonary arterial pressure
were 38 and 60 mmHg, respectively, without any electro-
cardiographic alterations. CPB was restarted. Following
20 min of CPB assistance and a complete hemodynamic
recovery, the CPB was weaned. A transesophageal echo-
cardiography did not show any cardiac anomalies. At that
time, an isolated pulmonary vascular reaction to protamine
was suspected and only half-dose of the necessary prot-
amine was infused very slowly via the arterial cannula,
40 min after having stopped the second CPB. However,
once again, the patient responded with a marked blood
pressure drop, with the mean index of systemic vascular
resistance of 860 dyne s cm25 and pulmonary hypertension
simultaneously with global cardiac failure, 5 min after
completion of the protamine administration. We strongly
suspected an anaphylactic reaction to protamine. No cutane-
ous manifestations were present at any moment. CPB was
re-started, but this time without any myocardial recovery
despite the administration of inotrope drugs, steroids, and
anti-histamines. A Berlin Heart assist device (Fehling
Medical, D-13355 Berlin, Germany) was implanted and
the CPB could be stopped without administration of any
protamine. Suddenly, ventricular fibrillation occurred and
after prolonged unsuccessful reanimation associated to
ventilation difficulties with increased airway resistance
and resultant fall in PaO2, the patient succumbed in the
operating room. The autopsy failed to demonstrate any
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cardiac or pulmonary anomalies but showed a generalised
vascular eosinophilia, suggesting a severe anaphylactic
shock in response to the administration of protamine.
2. Discussion
Protamine is a polycationic polypeptide belonging to a
group of low molecular proteins contained in fish sperm. It
is used extensively to neutralize heparin following cardiac
and vascular surgical procedures, but it is also used in
dialysis and leucopheresis. Another major use of protamine
occurs in the complexing of insulin to delay absorption and
prolong duration of action. When injected intravenously, the
basic reacting protamine combines with the acidic heparin
to form a neutral salt, thus eliminating the anticoagulating
properties of heparin.
Adverse responses to protamine have been identified for
many years. The incidence of such adverse reactions has
been reported as varying from 0.06 to 10.6% [2]. They have
been reported in patients with fish allergy, in those pre-
viously exposed to protamine, principally diabetics who
have received protamine zinc insulin. In addition, both
vasectomised and infertile men have a theoretical risk of
sensitivity via antibodies raised to protamine, contained in
sperm released into the blood stream. The incidence of
catastrophic reactions to protamine during cardiovascular
surgery is reported to be 0.13% [3]. Although the exact
mechanisms by which protamine produces anaphylaxis are
not completely understood, some possible mechanisms are
described. Protamine may act as an antigen and bind to the
IgE antibodies. This process may lead to cross-linking with
the antibody surfaces, which then initiates a process of cell
degranulation. Adverse reactions may also be associated
with the interaction between protamine and complement-
fixing antiprotamine IgG antibodies. Protamine binds to a
cell. Circulating IgG antibodies recognize the drug as an
antigen and bind with the protamine. The cell-bound IgG
activates the complement system. Moreover, adverse
responses to protamine seem to be related to the formation
of protamine–heparin complexes, which appear to activate
the classical complement cascade with subsequent gener-
ation of anaphylatoxins [4]. Protamine adverse reactions fall
into three different categories: transient systemic hypo-
tension related to rapid drug administration, anaphylactoid
reactions, and catastrophic pulmonary vasoconstriction [5].
Anaphylactoid responses to protamine are characterized by
edema of the skin, mucosa, and viscera, decreased systemic
vascular resistance, bronchospasm, and occasionally flush-
ing. Catastrophic pulmonary vasoconstriction is accom-
panied by right ventricular dilation, pulmonary arterial
hypertension, decreased left ventricular filling pressure, and
systemic hypotension. This type of reaction appear to occur
in patients with abnormal pulmonary hemodynamics [5].
A well-controlled study [6] with constant monitoring of
cardiac output, systemic blood pressure, and ventricular
pressures of patients during protamine infusion after CPB
established that protamine causes significant reduction in
peripheral vascular resistance. Hypotension occurred when
the increase in cardiac output was insufficient to offset the
decreased peripheral resistance. A small reduction in left
ventricle contractile activity is present only in patients with
a decrease .10 mmHg in systemic blood pressure.
However the precise mechanism that explains protamine-
mediated systemic hypotension is unknown. Evora et al. [7]
reported that pulmonary circulation is extensively involved
in protamine-mediated effects on endothelial function.
In vitro organ chambers and canine pulmonary artery
studies indicate that protamine induces endothelium-
dependent vasodilation, instead of a vasoconstriction, as
previously documented [5]. Heparin, in contrast to the
systemic circulation, inhibits the endothelium-dependent
vasodilation to protamine [7]. However, this inhibitory
effect can be overcome by higher doses of protamine,
concluding that protamine complexed with heparin does not
induce vasodilation. As in the systemic circulation, the
precise mechanism is still unknown. Since the direct effect
of protamine is vasodilation due to EDRF/NO release, it
appears that this vasoconstriction may be secondary. It is
possible that the protamine use for anticoagulation reversion
causes release of thromboxane, which induces catastrophic
pulmonary vasoconstriction [8]. Horrow [5], who reported
multiple animal studies, demonstrated a depressed ventri-
cular contractility and thrombocytopenia. In our case, we
observed similar reaction with a pulmonary hypertension, a
dramatic decrease of the systemic blood pressure accom-
panied by major depression of ventricular contractility.
Multiple studies demonstrated increased cardiovascular
effects with rapid injection of protamine [5]. The American
Hospital Formulary Service recommendation for dosing is
“no more than 50 mg of the drug is administered in any
10-min-period” [9]. We think that a major step in the
surgical outcome of our patient was the decision to again
administer protamine after the weaning of the second CPB
period. This decision was initially taken because we did
not think that we were dealing with a protamine-related
anaphylactic reaction, as there was no drop in peripheral
resistances and the patient completely recovered under CPB
assistance. After the second administration of protamine,
cardiac failure was global and unfortunately irreversible
despite the prolonged CPB assistance and implantation of
an external ventricular assist device (Berlin Heart). The
mechanism of this irreversible cardiac failure remains
unexplained and supports the hypothesis of a direct effect
of the heparin–protamine complexes on cardiac contrac-
tility [5]. At the present time, no alternatives to the use of
protamine are available. Hexadimethrine bromide (poly-
brene) and some heparinases are agents that have been used
occasionally as reversal agents for heparin. Both have
significant side effects.
In the absence of a safe and efficient agent for the
reversal of heparin, when the risks of adverse reaction to
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protamine outweigh the risks of extensive bleeding,
spontaneous reversal of heparin is allowed. We estimate
that this strategy should have been used in our patient after
the first major hemodynamic alteration. Treatment of
adverse responses to protamine is based on supporting the
affected organs and reducing the effects of histamine.
Aggressive resuscitative efforts must be initiated immedi-
ately including restoration of CPB, when still available.
Viaro et al. [10] suggest methylene blue as a novel experi-
mental approach to prevent and treat hemodynamic
complications caused by the use of protamine after CPB.
According to them, six patients presented an anaphylactoid
type adverse reaction to protamine and were treated
successfully with methylene blue ‘bolus’ infusion of
1.5 mg/kg (120 mg), followed by continuous infusion of
another 120 mg diluted in 5% of glucose in water. The
anaphylactic manifestation reversion was complete in
10–15 min. Immunologic reactions to protamine have
received little attention among clinicians. In view of our
experience, we should like to suggest that anaphylactic
reactions to protamine are uncommon but potentially deva-
stating. Patients, who have had previous protamine injec-
tions during cardiovascular surgery, diabetics on protamine
containing insulin, as well as patients with allergy to fish
and vasectomised patients should perhaps be routinely
tested for such sensitivity and be appropriately premedi-
cated. Finally, when suspecting a severe adverse reaction to
protamine, we estimate that heparin should not be reversed
even with a greater risk of bleeding and subsequent
re-exploration. It is hoped that the future will also provide
increased knowledge to prevent and improve patient
outcomes related to adverse response to protamine.
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